Novartis AG’s (NOVN.EB) biosimilars division Sandoz has signed a global agreement with Polpharma SA for the commercialization of a proposed natalizumab biosimilar, the company said Tuesday.
The medicine is in phase 3 clinical development for the treatment of relapsing-remitting multiple sclerosis, Novartis said.
Under the deal, Polpharma will maintain responsibilities for development, manufacturing and supply of proposed biosimilar natalizumab. Sandoz will commercialize and distribute the medicine in all markets upon approval, through an exclusive global license, the company said.
Other terms of the agreement are confidential, it said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.